NDA submission with strong Phase 3 data de-risks encaleret's approval path for ADH1. Watch for FDA acceptance and priority review decision, which could accelerate timeline. Expansion into chronic hypoparathyroidism (RECLAIM-HP) represents a larger market opportunity. Monitor for any FDA advisory committee meeting or CRL risk.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $65.95entry
- T+1 · 6mo ago +4.03%α +3.46% · $68.61
- T+5 · 6mo ago −0.96%α −1.03% · $65.32
- T+20 · 5mo ago +2.21%α +3.93% · $67.41
- T+60 · 3mo ago +25.55%α +21.17% · $82.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio announced NDA submission to the FDA for encaleret in ADH1, supported by positive Phase 3 CALIBRATE data showing 76% of patients achieved target calcium levels vs 4% on standard of care (p<0.0001). If approved, encaleret would be the first approved therapy for ADH1, with a potential U.S. launch in early 2027 and an estimated diagnosed patient population of ~2,000 in the U.S.
Key Facts
- NDA submitted to FDA for encaleret in autosomal dominant hypocalcemia type 1 (ADH1)
- Phase 3 CALIBRATE trial met all primary and key secondary endpoints
- 76% of encaleret patients achieved target serum and urine calcium vs 4% on conventional therapy (p<0.0001)
- Encaleret restored endogenous PTH in 91.1% of patients vs 0% on standard of care at Week 24
- No discontinuations in encaleret arm; favorable safety profile
- Potential first approved therapy for ADH1; U.S. launch anticipated early 2027
- Nearly 2,000 diagnosed ADH patients in U.S. since Oct 2023 based on claims data
- MAA submission to EMA planned for H2 2026
- Phase 2/3 pediatric study (CALIBRATE-PEDS) enrolling; Phase 3 chronic hypoparathyroidism study (RECLAIM-HP) planned for Summer 2026
- Fast Track and Orphan Drug designations from FDA; Orphan in EU and Japan
Financial Impact
First-to-market therapy for ADH1 with ~2,000 diagnosed U.S. patients; potential expansion to chronic hypoparathyroidism (larger market). No revenue guidance provided.
Risk Factors
- FDA may not accept NDA or may issue Complete Response Letter
- ADH1 is ultra-rare (~2,000 diagnosed patients) limiting peak revenue potential
- Competition from existing calcium/vitamin D therapies and potential future entrants
- Regulatory delays or additional clinical data requirements
- Commercial execution risk in a rare disease with small prescriber base
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292712 |
Track record
38 reports on BBIO
9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers